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High HIV Incidence among Persons Who Inject Drugs in
Pakistan: Greater Risk with Needle Sharing and Injecting
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Abstract
Background: The incidence of HIV among persons who inject drugs (PWIDU) has fallen in many nations, likely due to
successes of clean needle/syringe exchange and substance abuse treatment and service programs. However in Pakistan,
prevalence rates for PWID have risen dramatically. In several cities, prevalence exceeded 20% by 2009 compared to a 2003
baseline of just 0.5%. However, no cohort study of PWID has ever been conducted.
Methods: We enrolled a cohort of 636 HIV seronegative PWID registered with three drop-in centers that focus on risk
reduction and basic social services in Karachi. Recruitment began in 2009 (March to June) and PWID were followed for two
years. We measured incidence rates and risk factors associated with HIV seroconversion.
Results: Incidence of HIV was 12.4 per 100 person-years (95% exact Poisson confidence interval [CI]: 10.3–14.9). We followed
474 of 636 HIV seronegative persons (74.5%) for two years, an annual loss to follow-up of ,13 per 100 person years. In
multivariable Cox regression analysis, HIV seroconversion was associated with non-Muslim religion (Adjusted risk ratio
[ARR] = 1.7, 95%CI:1.4, 2.7, p = 0.03), sharing of syringes (ARR = 2.3, 95%CI:1.5, 3.3, p,0.0001), being homeless (ARR = 1.7,
95%CI:1.1, 2.5, p = 0.009), and daily injection of drugs (ARR = 1.1, 95%CI:1.0, 1.3, p = 0.04).
Conclusions: Even though all members of the cohort of PWID were attending risk reduction programs, the HIV incidence
rate was very high in Karachi from 2009–2011. The project budget was low, yet we were able to retain three-quarters of the
population over two years. Absence of opiate substitution therapy and incomplete needle/syringe exchange coverage
undermines success in HIV risk reduction.
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Khan in Punjab province the prevalence has reached 52.5% and
49.6% respectively. In Sargodha the second documented HIV
outbreak was reported in 2007 when out of 400 recruited PWID
more than half (51.3%) were confirmed positive [8]. In Gujrat, a
relatively small town of Punjab province, 46.2% PWID were
positive [7]. This is the same town where in 2008 in an HIV
screening camp, out of 246 persons fully 35.8% were HIV positive.
This new outbreak attracted attention and the Field Epidemiology
and Laboratory Training Program of CDC conducted an
investigation. Injection of illicit drugs was the principal cause [9].
PWID are now the principal drivers of the HIV epidemic in
Pakistan, yet the quality of harm reduction services remains far
below acceptable standards. The first harm reduction program was
initiated in Karachi in 2000 and with passage of time at least three
non-governmental organizations (NGOs) had been providing

Introduction
The HIV epidemic in Pakistan began in 1986 when a foreign
sailor died of AIDS in Karachi; local transmission was documented in 1987 [1,2]. For almost 20 years, most cases were imported
[3]. In 2003, the prevalence of HIV among persons who inject
drugs (PWID; also known as injection drug users) was 0.6% in
Karachi, Pakistan’s major port and largest city [4]. The first
outbreak of HIV among PWID was documented in June 2004 in
Larkana, a city of half a million persons in Sindh Province, when
17 of 183 (9.3%) PWID tested HIV seropositive [5,6]. From 2003
to 2007, HIV prevalence among PWID in Karachi rose from
0.3% to 23% in 2004 and has reached 42% in 2011 [6,7]. The
findings of 2011 national surveillance showed an extremely high
prevalence in other cities of Pakistan [7]. In Faisalabad and DG
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Table 1. Descriptive characteristics of 474 injection drug
users followed for two years in a Karachi, Pakistan cohort.

Table 1. Cont.

Characteristic
Characteristic

n (%)

Age (mean in years ± S.D.)

30.069.0

HIV serostatus at the end of the cohort period

n (%)

Yes

9 (1.9)

No

465 (98.1)

Knows that HIV spreads through unprotected sex

Positive

118 (24.9)

Yes

49 (10.3)

Negative

356 (75.1)

No

425 (89.7)

Source of registration in the study

Typical location of drug use

Outreach

361 (76.2)

Home

69 (14.6)

Othersa

113 (23.8)

Street

405 (85.4)

Religion

Living in streets

Muslim

418 (88.2)

No

203 (42.8)

Christian

54 (11.4)

Yes

271 (57.2)

Hindu

2 (0.4)

Frequency of daily drug use (mean and S.De)

3.761.4

Ethnicity

a

Sindhi

225 (47.5)

Non Sindhib

249 (52.5)

Government organization, non-governmental organization, community, and
friends.
b
Non-Muslim included 54 Christians and 2 Hindus vs. 418 Muslims.
c
Approximately 90 rupees per US dollar in this time period, such that 5000
rupees<US$ 56.
d
Pharmacy, friends, and hospital garbage.
e
Drop-in center (DIC) and mobile service unit (MSU).
doi:10.1371/journal.pone.0081715.t001

Education
Some formal education

130 (27.4)

No formal education

344 (72.6)

Professional skills
None

280 (59.1)

Some

194 (40.9)

services in this megacity of over 20 million persons. However, NGO
program coverage has remained low and has not reached more than
16% of the target estimated population of PWID [10]. There are no
opiate/opioid substitute therapy (OST) programs in Karachi for
treatment of addiction. The available choices are limited to 2–4
weeks of detoxification via ‘‘cold turkey’’ methods, ameliorated only
with analgesics. There is dearth of data on actual relapse rates but
the program managers of harm reduction program quote a relapse
rate figure of .80% among PWID (at least one has told us that it is
100%).
Risk factors and prevalence of HIV and other blood-borne
infections among PWID are documented in diverse Pakistani
venues [4–37]. However, no incidence study has been published
and it is not known to what extent PWID could be followed
successfully in Pakistan. We measured HIV seroincidence and
factors associated with HIV seroconversion among PWID enrolled
in three drop-in centers in Karachi for two years.

Currently sharing of needles/syringes
Yes

101 (21.3)

No

373 (78.7)

History of arrest, ever
No

222 (46.8)

Yes

252 (53.2)

Physical disability
Yes

14 (3.0)

No

460 (97.0)

Marital status
Married

220 (46.4)

Un-married

254 (53.6)

Monthly income in rupeesc
,5000

277 (58.4)

.5000

197 (41.6)

Methods
Setting

Last syringe used
New

422 (89.0)

Used

52 (11.0)

The study was conducted in Karachi, the nation’s major seaport
and economic hub, most populous city, and the capital of Sindh
Province. The population is estimated at more than 20 million
persons with high diversity of ethnic groups [38]. Karachi has an
estimated 16,500 PWID [17], though this may be a minimum
estimate given sampling uncertainties. We conducted our study at
three drop-in centers that provide basic harm reduction and social
services to PWID exclusive of opiate substitution therapy; the
NGO that runs the drop-in centers has been working with PWID
since 1994.

Source of syringe
Drop-in-centers (DIC) and mobile service units (MSU)

160 (33.8)

Othersd

314 (66.2)

Know about HIV/AIDS
Yes

24 (5.1)

No

450 (94.9)

Know about dangers of needle sharing
Yes

21 (4.4)

Sample size

No

453 (95.6)

The sample size was determine keeping in mind that the persons
using the needle exchange services with fidelity might have an
HIV seroincidence of 5% per year compared to a higher rate of
12% per year in the lower-user group. Using Open-Epi, both the

Ever treated for sexually transmitted infection
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ment of Pakistan HIV Testing strategy of positivity on two
different ELISAs (Murex HIV Ag/Ab CombinationTM, AbbottMurex. Ltd, and AniLabsystems HIV EIATM kit, LabsystemsMultiscan MS, Labsystems, Finland). Dual ELISA confirmed
PWID were assessed for combination antiretroviral therapy
eligibility by clinical assessment and CD4+ cell counts in the
Reference Lab. Only persons seroreactive on the rapid test and
two confirmatory tests were considered to be HIV seroconverters.
All confirmed HIV seropositive clients were enrolled into the
Antiretroviral Treatment Center of the Sindh AIDS Control
Program for care and antiretroviral treatment if WHO and
national guideline eligibility for therapy was met (CD4+ cells
,350/mL and/or WHO clinical status 3 or 4).

Fleiss and the Kelsey approaches required 250 persons per group
(higher and lower program utilizers). Since loss to follow up is very
high among IDUs in such programs we assumed that 30% of
IDUs would be lost to follow up over two years, suggesting that we
would need 650 persons. Since we had lower-than-expected loss to
follow-up, our 636 study participants recruited into our study who
were enrolled in the program during March–June 2009 were
adequate to address the research question with a two-sided
significance level of 95% and a statistical power of 80%.

Design
We recruited 636 injection drug users and followed them until
they were lost-to-follow up or the end of the two year study from
March 2009 to June 2011, for the estimation of incidence rate and
risk factors associated with HIV seroconversion. We excluded
eight persons at baseline who were unable to understand the study
objectives due to disabilities that precluded provision of informed
consent.

Ethical considerations
Ethics Review Board of Aga Khan University specifically
approved this study. Privacy and confidentiality of the participants
were assured at all levels of study. Data were password protected to
which only the principal investigator had access. Written informed
consent was obtained from all eligible study participants. The
study participants had the right to refuse blood tests or interviews
and could withdraw from the study at any time without
compromising their access to the services of the drop-in centers.
No monetary incentive was offered. The project budget from the
Fogarty International Center was US$5000 for two years, along
with a research training stipend for the principal investigator
(RNS). With the knowledge and consent of the client, results for
HIV positive PWID were shared with the NGO director such that
HIV care services could be offered.

Follow up visits and tracking the study participants
The follow up visits by the outreach workers were on daily basis.
Three investigators (RS, AA and SAS) visited on a monthly basis.
The participants were tracked by the staff of the risk reduction
programs. The ‘‘in-charges’’ of the drop-in centers were in touch
with the participants during whole study period, though some
were lost to follow-up.

Techniques used to track the participants
The participants were tracked by the staff of the risk reduction
programs. The ‘‘in-charges’’ of the drop-in centers were in touch
with the participants during whole study period, though some
were lost to follow-up.

Data collection
The data were collected through a field-tested questionnaire,
developed in English and translated into Urdu. The data collectors
were trained interviewers who had previous experience of working
with the PWID. The data were collected on socio-demographics,
risk behaviors, drug history, and knowledge of HIV/AIDS.

Laboratory testing
The initial rapid test screening of the study participants was
done with the SD BIOLINE HIV-1/2 3.0 testTM (Standard
Diagnostics, Inc., Korea). The clients reactive on the rapid test
gave 5 mL venous blood for confirmatory testing at the Referral
Laboratory of the Sindh AIDS Control Program, Civil Hospital
Karachi, for confirmation using the UNAIDS/WHO/Govern-

Statistical analyses
Data entry and analysis. Data were entered into EpiInfoTMversion 6.0 (Centers for Disease Control and Prevention) and

Table 2. Sensitivity analysis of the estimates for HIV incidence per 100 person-years (py) with 95% exact Poisson confidence
intervals (CI), considering persons lost to follow-up (LTFU) in a variety of plausible ‘‘high-low’’ scenarios for their unknown
incidence.

Scenario

Events

Person-time

Incidence per 100 py

Standard error

Exact lower
95% CI

Exact upper
95% CI

Do not adjust for LTFU
(use observed data only)

118

948

12.4

1.15

10.3

14.9

Assume 17.4% of LTFU are
HIV+ (30% lower than observed)

146

1272

11.5

0.95

9.69

13.5

Assume 20% of LTFU are
HIV+ (same as observed)

150

1272

11.8

0.96

9.98

13.8

Assume 24.9% of LTFU are
HIV+ (same as observed)

158

1272

12.4

0.99

10.6

14.5

Assume 30% of LTFU are HIV+

167

1272

13.1

1.02

11.1

15.3

Assume 32.4% of LTFU are
HIV+ (30% higher than observed)

170

1272

13.4

1.03

11.4

15.5

HIGH-LOW RANGE OVER ALL
ASSUMPTIONS

11.5–13.4

9.7–15.5

doi:10.1371/journal.pone.0081715.t002
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analyzed using the Statistical Package for Social Sciences
(SPSSTM) version 17 and OpenEpiTM version 2.3.1. Exact
confidence intervals were calculated using R statistical software,
version 2.13.1 (available at: http://www.R-project.org; R Foundation for Statistical Computing, Vienna, Austria). Data were
double entered by the two independent data entry staff and
discrepant entries were checked for accuracy and resolution.
Frequencies were calculated for categorical data; means and
standard deviations were calculated for the continuous variables.
The estimated date of seroconversion was determined as the midpoint between last negative and first positive test. The incidence
rate was defined as the total number of incident cases per 100
person-years contributed. Both confidence intervals and sensitivity
analyses were assessed with exact Poisson methods. Sensitivity
analyses were based on plausible ‘‘high-low’’ assumptions for
incidence among lost to follow-up subjects. All biologically or
behaviorally important variables were selected for univariate
analyses to estimate unadjusted risk ratios (RR) and 95%
confidence intervals (95%CI). All variables associated with
seroconversion at p#0.2 were included in a multivariable Cox
regression model. Confounding was assessed by a 10% change in
beta coefficient of any independent variable in the model.

Table 3. Univariate regression analysis of factors associated
with seroconversion in a cohort of 474 injection drug users
followed for two years in Karachi, Pakistan.

Variable

95% CI

p-value

1.3

0.9, 1.9

0.2

1.7

1.1, 2.7

0.02

0.9

0.6, 1.3

0.6

1.2

0.8, 1.9

0.4

2.4

1.7, 3.5

,0.0001

1.0

0.7, 1.5

0.9

2.0

0.9, 4.4

0.06

1.0

0.7, 1.4

0.9

1.5

1.0, 2.1

0.04

1.6

1.1, 2.5

0.02

1.3

0.4, 4.2

0.6

1.7

1.2, 2.5

0.008

1.1

1.0, 1.3

0.03

Source of registration
Othersa (vs Outreach)
Religion
Non Muslimsb (vs. Muslim)
Ethnicity
Non Sindhic (vs. Sindhi)
Education
Illiterate (vs. Literate)
Currently Sharing of needles/syringes
Yes (vs. No)
History of arrest
Yes (vs. No)
Physical disability
Yes (vs. No0

Results

Marital status
Unmarried (vs. Married)

All participants were seronegative at the beginning of the study,
as per the study design. The retention rate of the PWID in the
program was 474 of 636 (74.5%) over the 2 year period, a loss-tofollow-up rate of just less than 13 per 100 person years. Excluding
the 162 men lost to follow-up 2 years, study we had confirmed 118
(24.9%) HIV seropositive and 356 (75.1%) HIV Seronegative
PWID (Table 1), at the end of the study (24 month follow-up).
HIV incidence was 12.4 per 100 person-years among PWID
enrolled, with 95% exact Poisson CI: 10.3–14.9 (Table 2). Over a
variety of plausible assumptions for the men lost to follow-up
(LTFU), sensitivity analyses suggested our study to be robust in its
estimate of incidence. If the two extremes are used, one might
assume 17.4% of LTFU were HIV-infected (30% lower than
observed), such that the HIV incidence would be 11.5 per 100
person-years (95% CI: 9.69–13.5). In contrast, one might assume
32.4% of LTFU were HIV-infected (30% higher than observed),
such that the HIV incidence would be 13.4 per 100 person-years
(95% CI: 11.4–15.5).
The mean age of PWID in one of the three drop-in risk
reduction programs was 30.069.0 years. Active outreach was the
major source of enrollment (n = 361, 76.2%) into the study. Most
clients (n = 418, 88.2%) were Muslims, while Christians represented 11.4% (n = 54) and Hindus 0.4% (n = 2). No formal
education was reported by 344 (72.6%) of participants and 280
(59.1%) reported having no work skills. About one of five
participants reported sharing needles/syringes (n = 101, 21.3%).
Most participants (n = 252, 53.2%) had a history of prior arrest.
Most participants were destitute with 277 (58.4%) having an
income ,5000 rupees per month (equivalent in 2009 to US$75/
month). About half of the participants (n = 254, 53.6%) were
unmarried. Most participants (n = 282, 59.5%) reported 2–4
episodes of drug injecting/day. Most participants (n = 314,
66.2%) were getting syringes from sources other than the dropin centers or the mobile service units.

Monthly income Pakistani rupeesd
,5000 (vs. $5000)
Source of syringes/needles
Othere (vs. DIC & MSU)f
Ever treated for sexually transmitted
infection
Yes (vs. No)
Home
Homeless (vs. having home)
Daily frequency of injections (#/day)
a

Government organization, non-governmental organization, community, and
friends.
b
Non-Muslim included 54 Christians and 2 Hindus vs. 418 Muslims.
c
Non-Sindhis included Pathan, Punjabi, Hindko, Kashmiri, and Bengali.
d
Approximately 90 rupees per US dollar in this time period, such that 5000
rupees<US$ 56.
e
Pharmacy, friends, and hospital garbage.
f
Drop-in center and mobile service unit.
doi:10.1371/journal.pone.0081715.t003

(p,0.0001), homelessness(p = 0.008), non-Muslim religion
(p = 0.02), source of syringes other than the drop-in centers or
mobile service units (p = 0.02), daily frequency of injecting drugs
(p = 0.03), monthly income ,PKR 5,000 (p = 0.04), physical
disability (p = 0.06), and source of registration other than outreach
(p = 0.2). In multivariable analysis, four factors remained as
significant predictors of seroconversion (Table 4): sharing of
syringes (ARR = 2.3, 95%CI: 1.5, 3.3, p,0.0001); non-Muslim
religion (ARR = 1.7, 95%CI:1.4, 2.7, p = 0.03); being homeless
(ARR = 1.7, 95%CI:1.1, 2.5, p = 0.009); daily frequency of
injecting drugs (ARR = 1.1, 95%CI:1.0, 1.3, p = 0.04).

Discussion

Predictors of seroconversion

The high incidence rate documented in our cohort (12.4 per
100 person-years) is likely a minimum HIV incidence rate for
PWID in Karachi, given that, for ethical reasons, the PWID
recruited were followed within the context of local risk reduction

Eight factors were associated with seroconversion among the
474 persons in univariate analyses (Table 3) and were included in
the multivariable Cox regression analysis: sharing of syringes
PLOS ONE | www.plosone.org
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Table 4. Multivariable Cox regression analysis for associations with HIV seroconversion in a two-year cohort of injection drug users
in Karachi, Pakistan (n = 474).

Variable

Adjusted Risk Ratio

95% CI

p-value

1.1

0.8, 1.8

0.4

1.7

1.4, 2.7

0.03

2.3

1.5, 3.3

,0.0001

1.7

0.8, 3.7

0.2

1.2

0.9, 2.3

0.06f

1.5

0.9, 2.3

0.009

1.1

1.0, 1.3

0.04

Source of registration
Othersa (vs Outreach)
Religion
Non Muslimsb (vs. Muslim)
Currently Sharing of needles/syringes
Yes (vs. No)
Physical disability
Yes (vs. No0
Monthly income Pakistani rupeesc
,5000 (vs. $5000)
Source of syringes/needles
Otherd (vs. DIC & MSU)e
Daily frequency of injections (#/day)
a

Government organization, non-governmental organization, community, and friends.
Non-Muslim included 54 Christians and 2 Hindus vs. 418 Muslims.
Approximately 90 rupees per US dollar in this time period, such that 5000 rupees<US$ 56.
d
Pharmacy, friends, and hospital garbage.
e
Drop-in center (DIC) and mobile service unit (MSU).
f
If source of registration, physical disability, and monthly income, are excluded from the above Cox regression to achieve a more parsimonious model, then the effect
sizes are similar and source of syringes becomes a significant predictor (p = 0.046).
doi:10.1371/journal.pone.0081715.t004
b
c

group when someone is infected with HIV, spreading the infection
in the whole group due to sharing of needles and syringes.
Studies from around the world have shown the importance of
needle/syringe sharing for HIV acquisition [41,42]. Living on the
streets exposes PWID to health hazards, sexual abuse, and more
risky behaviors as compared to those who live in homes. Many
Karachi homeless PWID live near garbage dumps where food and
needles can be scrounged. The experience of our drop-in care
providers suggests that PWID living in streets are prone to sell sex
for drugs, free injections, or money. We found, too, that as the
frequency of injecting drugs per day increases, the risk of HIV
acquisition increases, a logical relationship also seen in Vancouver,
Canada [41].
The high incidence rate among clients of harm reduction
program should be alarming for Pakistani and global public health
and welfare officials and other stakeholders. In Pakistan,
conservative socio-cultural norms often fail acknowledge IDU as
a priority concern; this limits prevention investments such that
program coverage and services of risk reduction and drug
treatment programs in Karachi are low. Opiate agonist therapy
is almost completely unavailable, for example, and the only
buprenorphine pill available is such a low dose as to be almost
homeopathic. Underfunding compromises the quality and quantity of outreach services and the full implementation of risk
reduction programs. Quality improvement feedback mechanisms
based on modern monitoring and evaluation programs are largely
missing from risk reduction programs [17,18]. All these program
deficits contribute to the exceedingly high incidence rates.
Barriers to scale-up of needle/syringe exchange programs and
of opiate/opioid substitution therapy are many [43–45]. Lack of
political will, lack of funds (against other perceived needs), stigma
biasing policy makers against assistance for risk reduction about
PWID, and legal obstacles are a few of these. Unless scaling up of
risk reduction programs for PWID, Pakistan cannot expect any of

programs. The incidence rate among active PWID not attending
the drop-in centers is likely even higher. PWID in Sichuan
Province (China), St. Petersburg (Russia), Xinjiang Province
(China), and Bangkok (Thailand) have been followed with
seroincidence rates of 3.2, 4.5, 8.8, and 5.8 per 100 person-years
respectively [36–39]. Hence our incidence data may be among the
highest yet reported in Asia or Eastern Europe where PWID
continue to play a dominant role in driving HIV transmission.
Our study was conducted at exceedingly low cost; we think the
13% annual loss to follow-up could be reduced if the cohort were
being followed in a funded clinical trial with research resources.
Nevertheless, our retention rate was better than we anticipated,
suggesting that drop-in centers might be an excellent venue for
engagement of high risk PWID in order to offer them locally
available harm reduction. Mitigation of IDU medical and social
consequences would be an expected favorable consequence of
expanding risk reduction service coverage to all PWID, if high
quality and coverage could be maintained.
In Karachi’s last census (1998), Christians represented 2.4% of
the population, but current estimates for a Karachi in 2011 are
that Christians represent ,1% of Karachi’s population. Yet
Christians were disproportionately represented among PWID,
11.4% in our cohort, and also were overrepresented in
seroconverters (Table 1). This finding was noted alongside more
familiar risks for HIV acquisition: needle/syringe sharing,
homelessness, and higher frequency of drug injection. PWID
who belong to a religious and cultural minority might face real or
perceived challenges in access and utilization of the program
services, though all our subjects were in the same risk reduction
program. They might be discriminated against in society, e.g., in
job seeking and have other difficulties in social interaction. They
might inject drugs in a closed group having similar socio-cultural
characteristics [40]. The risk of HIV might increase in such a
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the successes seen in so much of Asia in reduced incidence among
PWID [46,47]. HIV testing must be expanded in this population,
along with facilitated linkage to HIV care and social services, both
to benefit infected PWID and to reduce their infectiousness to
others [48–51]. PWID are a risk to the general population given
that they mix with female and male sex workers, prisoners, and
spouses, as well as contribute blood for pay to illicit blood
collection agencies [52,53,62]. New highways better connect cities
within Sindh Province as well as to other regions in Pakistan where
HIV prevalence has been lower, risking further spread of virus
[54–56].
The principal strength of our study is that it is unique, the firstever documentation from Pakistan of the incidence rate of HIV
among PWID. True seroincidence rates are hard to come by,
given the complexity of cohort assembly and follow-up. Given that
our research budget was low, we believe that a 74% follow up rate
over two years was encouraging. A limitation is that our study was
a prospective study within a risk reduction program context, so we
cannot generalize our findings to persons not attending the drop-in
centers and those not in Karachi. We do not know the incidence
rates for those who were lost to follow up and were not retained in
the harm reduction program, but it is reasonable to assume that
they might have been even higher than among men in the risk
reduction programs. Another limitation was that we did not backtranslate our questionnaires. However, the translators were
bilingually fluent and the investigators, also bilingual, found the
translations to have full fidelity with the original in English, so we
do not believe that this affected our results. We mention this
limitation in the Discussion section.
The HIV incidence rate among PWID enrolled in harm
reduction programs at Karachi is alarming, perhaps among the

highest in the world in the 2009–2011 time period. Timely and
appropriate programmatic initiatives are needed to avert both
increased disease burden and expanded transmission to the
general population [57–61]. More work is needed in risk of
hepatitis transmission and in the molecular epidemiology of IDUrelated transmission [62–64]. Coverage of and fidelity (adherence)
to clean needle use in the context of needle and syringe exchange
are critical elements needing quality improvement [65–73].
Research into innovative, promising improvements in risk
reduction, drug treatment, and HIV prevention are feasible in
this context, given our success in cohort implementation and the
high documented seroincidence rates. Expanded needle/syringe
exchange, detoxification and rehabilitation services, and use of
opioid agonist therapy in harm reduction and drug treatment
programs can play an instrumental role in mitigating the dual
burden of HIV infection and drug addiction in Pakistan [45,74–
76].
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